JP6291502B2 - ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 - Google Patents

ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 Download PDF

Info

Publication number
JP6291502B2
JP6291502B2 JP2015539868A JP2015539868A JP6291502B2 JP 6291502 B2 JP6291502 B2 JP 6291502B2 JP 2015539868 A JP2015539868 A JP 2015539868A JP 2015539868 A JP2015539868 A JP 2015539868A JP 6291502 B2 JP6291502 B2 JP 6291502B2
Authority
JP
Japan
Prior art keywords
compound
mmol
pyrazolo
chloro
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015539868A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535257A (ja
JP2015535257A5 (enExample
Inventor
ブーリ，ローランド・ワーナー
エスミュ，ウィリアム・ラメシュチャンドラ・クリシュナ
ロック，クリストファー・ジェームズ
マラグ，カリネ・ファビエンヌ
オーエンズ，アンドリュー・ペイト
ハート，ウィリアム・エドワード
Original Assignee
アッシャー・サード・イニシアティブ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アッシャー・サード・イニシアティブ・インコーポレイテッド filed Critical アッシャー・サード・イニシアティブ・インコーポレイテッド
Publication of JP2015535257A publication Critical patent/JP2015535257A/ja
Publication of JP2015535257A5 publication Critical patent/JP2015535257A5/ja
Application granted granted Critical
Publication of JP6291502B2 publication Critical patent/JP6291502B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2015539868A 2012-10-25 2013-10-25 ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 Active JP6291502B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261718611P 2012-10-25 2012-10-25
US61/718,611 2012-10-25
US201361775402P 2013-03-08 2013-03-08
US61/775,402 2013-03-08
PCT/US2013/066939 WO2014066836A1 (en) 2012-10-25 2013-10-25 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Publications (3)

Publication Number Publication Date
JP2015535257A JP2015535257A (ja) 2015-12-10
JP2015535257A5 JP2015535257A5 (enExample) 2016-12-15
JP6291502B2 true JP6291502B2 (ja) 2018-03-14

Family

ID=50545356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015539868A Active JP6291502B2 (ja) 2012-10-25 2013-10-25 ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法

Country Status (10)

Country Link
EP (1) EP2911671B1 (enExample)
JP (1) JP6291502B2 (enExample)
AU (1) AU2013334139B2 (enExample)
CA (1) CA2889494C (enExample)
ES (1) ES2687854T3 (enExample)
HU (1) HUE039970T2 (enExample)
IL (1) IL238288B (enExample)
PL (1) PL2911671T3 (enExample)
WO (1) WO2014066836A1 (enExample)
ZA (1) ZA201502655B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5902293B2 (ja) 2011-04-25 2016-04-13 アッシャー・サード・イニシアティブ・インコーポレイテッド ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
JP6290910B2 (ja) * 2012-10-25 2018-03-07 アッシャー・サード・イニシアティブ・インコーポレイテッド ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法
WO2017045955A1 (en) * 2015-09-14 2017-03-23 Basf Se Heterobicyclic compounds
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
IL279688B2 (en) * 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020161208A1 (en) 2019-02-06 2020-08-13 Syngenta Crop Protection Ag Herbicidal fused pyridazine compounds
WO2020161209A1 (en) 2019-02-06 2020-08-13 Syngenta Crop Protection Ag Herbicidal fused pyridazine compounds
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
EP4178580B1 (en) 2020-07-09 2025-11-05 Usher III Initiative, Inc. Bf 844 for use in the treatment of cancer
WO2023139091A1 (en) * 2022-01-19 2023-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Geralexin and uses thereof for the treatment of retinal degenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206723D0 (en) * 2002-03-21 2002-05-01 Glaxo Group Ltd Novel compounds
US20090306045A1 (en) * 2005-12-22 2009-12-10 Ira Mellman Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
WO2009062118A2 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
JP5902293B2 (ja) * 2011-04-25 2016-04-13 アッシャー・サード・イニシアティブ・インコーポレイテッド ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法
JP6290910B2 (ja) * 2012-10-25 2018-03-07 アッシャー・サード・イニシアティブ・インコーポレイテッド ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法

Also Published As

Publication number Publication date
AU2013334139B2 (en) 2017-08-03
EP2911671B1 (en) 2018-06-27
PL2911671T3 (pl) 2018-11-30
HK1214180A1 (en) 2016-07-22
IL238288B (en) 2018-04-30
CA2889494C (en) 2018-12-18
ZA201502655B (en) 2017-11-29
IL238288A0 (en) 2015-06-30
AU2013334139A1 (en) 2015-04-30
JP2015535257A (ja) 2015-12-10
EP2911671A4 (en) 2016-09-14
CA2889494A1 (en) 2014-05-01
ES2687854T3 (es) 2018-10-29
WO2014066836A1 (en) 2014-05-01
EP2911671A1 (en) 2015-09-02
HUE039970T2 (hu) 2019-02-28

Similar Documents

Publication Publication Date Title
JP2015535257A (ja) ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法
US9783545B2 (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
JP7208142B2 (ja) Ｒｈｏキナーゼ阻害剤としてのチロシンアミド誘導体
JP6770053B2 (ja) Ｒｏｃｋ阻害剤としてのフタラジノンおよびイソキノリノン
KR102868217B1 (ko) 돌연변이 p53 기능을 회복시키는 방법 및 화합물
AU2024227155A1 (en) Carboxy-benzimidazole GLP-1R modulating compounds.
CN102695710B (zh) 三环吡唑胺衍生物
US9187464B2 (en) TRPV4 antagonists
TW201734005A (zh) 用於治療纖維化之新穎化合物及其醫藥組合物
AU2012249801B2 (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome
US11981658B2 (en) Substituted aminopyridine compounds as EGFR inhibitors
CN121568936A (zh) 联芳基酰胺衍生物及其作为pkmyt1抑制剂的用途
AU2013334138B2 (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome
JP2009517333A (ja) 縮合複素環化合物
JPH08208602A (ja) インドロイルグアニジン誘導体
HK1214180B (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
CN101370812A (zh) 稠合的杂环化合物
HK1200451A1 (zh) 蛋白激酶抑制剂
HK1200451B (en) Protein kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161024

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180209

R150 Certificate of patent or registration of utility model

Ref document number: 6291502

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250